


AMENDMENT TO THE CLAIMS

1. (currently amended) A compound of formula 1



I

wherein:

- (i) n is an integer with a value ranging from ~~one~~ two to six;
- (ii) each R₁ is independently selected from:
 hydrogen,
 alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, aralkyl, aralkenyl,
 aralkynyl,
 halo, haloalkyl,
 hydroxyl, alkoxyl, hydroxyalkyl, alkoxyalkoxyl, acyl, carboxylate, carboxyl,
 alkanoyloxy,
 nitrate, nitrite, nitrile, cyanate, isocyanate, primary amino, secondary amino,
 tertiary amino, azido, carboxamido, acylamino,
 thiol, sulfonyl, alkyl sulfonate, aryl sulfonate, sulfonamide, thioaryloxy,
 thioalkoxy,
 oxygen heterocycles, nitrogen heterocycles and sulfur heterocycles;
- (iii) R₂, R₃ and R₅ are each independently selected from hydrogen, alkyl and cycloalkyl; and
- (iv) R₄ is selected from alkyl, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl and aralkyl,

provided that:

- a) when n is 1 or 2 and R₄ is tert-butyl, benzyl or methyl, the R₁s, R₂, R₃ and R₅ are not all hydrogens; and
- ~~b) when n is 1 and the R₁s are 4 dimethylamino, 4 methyl or 4 methoxy and the rest hydrogens and R₄ is methyl, R₂, R₃ and R₅ are not all hydrogens;~~
- ~~c) when n is 1 and the R₁s are 3,5 di tert butyls and the rest hydrogens and R₄ is tert butyl, R₂, R₃ and R₅ are not all hydrogens;~~
- ~~d) when n is 1 and R₄ is tert butyl or phenyl, and R₂ is methyl, the R₁s, R₃ and R₅ are not all hydrogens;~~
- ~~e) when n is 1 and R₄ is methyl or phenyl, R₅ is methyl, the R₁s, R₂, and R₃ are not all hydrogens;~~
- ~~f) when n is 1 and R₂ and R₄ are both methyls, the R₁s, R₃, and R₅ are not all hydrogens;~~
- ~~g) when n is 1, R₂ is methyl and R₄ is cyclohexyl or phenyl, the R₁s, R₃, and R₅ are not all hydrogens;~~
- ~~h) when n is 1, R₁s are 2,5 dimethyl or 2,5 dimethoxy with the remainder hydrogen and R₄ is cyclohexyl, R₃ and R₅ are not all hydrogens; and~~
- b) when n is 4 and R₄ is cyclohexyl the R₁s, R₂s, R₃s and R₅ are not all hydrogen.

2. (previously presented) The compound of claim 1 wherein the R₁ groups include hydrogens and from zero up to three nonhydrogens selected from alkyl, alkoxy,

alkoxyalkoxyl, hydroxy, amino, dialkylamino, acylamino, sulfonyl, sulfonate, sulfonamide, acyl, and aryl.

3. (previously presented) The compound of claim 1 wherein R₁ includes 1-5 halogens.
4. (currently amended) The compound of claim 1 wherein *n* is an integer having a value of from ± 2 through 4.
5. (currently amended) The compound of claim 1 wherein ~~*n* = 1 and R₂, R₃ and R₅ are together all hydrogen or two hydrogens and one lower alkyl; and materials in which *n*=2 or 3 and R₂, R₃ and R₅ are all hydrogens and up to two lower alkyls.~~
6. (currently amended) The compound of claim 2 wherein ~~*n* = 1 and R₂, R₃ and R₅ are together all hydrogen or two hydrogens and one lower alkyl; and materials in which *n*=2 or 3 and R₂, R₃ and R₅ are all hydrogens and up to two lower alkyls.~~
7. (previously presented) The compound of claim 5 wherein R₁ and R₄ are selected from the group consisting of:

R ₁	R ₄
H	C(CH ₃) ₃
4-Me	C(CH ₃) ₃
4-iso-Pr	C(CH ₃) ₃
4-OH	C(CH ₃) ₃
4-OMe	C(CH ₃) ₃
4-OCH ₂ OMe	C(CH ₃) ₃
4-OEt	C(CH ₃) ₃
4-NMe ₂	C(CH ₃) ₃
4-NHAc	C(CH ₃) ₃

R ₁	R ₄
4-F	C(CH ₃) ₃
4-Cl	C(CH ₃) ₃
2-SO ₃ Na	C(CH ₃) ₃
2,4-di-SO ₃ Na	C(CH ₃) ₃
3,5-di-t-Bu-4-OH	C(CH ₃) ₃
3,5-di-t-Bu-4-OCH ₂ OMe	C(CH ₃) ₃
2-OH	C(CH ₃) ₃
2-OEt	C(CH ₃) ₃

8. (currently amended) The compound of claim 1 selected from the group consisting of:

Compound 2 *N-tert*-butyl-C-{2-[4-(methoxymethoxy)phenyl]ethyl} nitrone

Compound 3 *N-tert*-butyl-C-[2-(4-hydroxyphenyl)ethyl] nitrone

Compound 4 *N-tert*-butyl-C-[2-(4-methoxyphenyl)ethyl] nitrone

Compound 5 *N-tert*-butyl-C-[4-(tetrahydropyran-2-yloxy) phenyl] nitrone

Compound 6 *N-tert*-butyl-C-[2-(4-isopropoxyphenyl)ethyl] nitrone

Compound 7 *N-tert*-butyl-C-[2-(4-ethoxyphenyl)ethyl] nitrone

Compound 8 *N-tert*-butyl-C-[2-(4-benzenesulfonyloxy)phenyl]ethyl] nitrone

Compound 9 *N-tert*-butyl-C-[2-(4-acetamidophenyl)ethyl] nitrone

Compound 10 *N-tert*-butyl-C-[2-(4-benzenesulfonamidophenyl)ethyl] nitrone

Compound 11 ~~*N-tert*-butyl-C-[2-(4-N,N-Dibenzenesulfimidophenyl)ethyl] nitrone~~ *N-tert*-butyl-C-[2-(4-N,N-dibenzenesulfimidophenyl)ethyl] nitrone.

Compound 12 *N-tert*-butyl-C-(5-phenylpentyl) nitrone

Compound 13 *N-tert*-butyl-C-[2-(4-isopropylphenyl)-1-methylethyl] nitrone

Compound 14 *N-tert*-butyl-C-(4-phenylpropyl) nitrone

Compound 15 *N-tert*-butyl-C-[1-(4-*tert*-butyl benzyl)-ethyl] nitrone

Compound 16 *N-tert*-butyl-C-[1-methyl-2-(4-methoxyphenyl)ethyl] nitrone

Compound 18 *N*-cyclohexyl-C-(2-phenylethyl) nitrone

Compound 19 *N-tert*-butyl-C-[4-phenylbutyl] nitrone

Compound 21 *N-tert*-butyl-C-[2-(3,5-di-*tert*-butyl-4-hydroxyphenyl)ethyl] nitrone

Compound 22 *N-tert*-butyl-C-[2-(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl] nitrone

Compound 23 *N-tert*-butyl-C-[4-methoxy-phenyl]propyl] nitrone,

and pharmaceutically acceptable salts thereof.

9. (currently amended) A nitrone compound having at least a Ph-Z-C(R)=N(=O)- where Ph represents a substituted or unsubstituted aryl moiety, and Z is a saturated aliphatic carbon chain of ~~one~~ two to six carbon atoms in length covalently bonded intermediate the aryl moiety and the nitrone carbon provided that:

when Z is -CH₂-CH₂-, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to either t-butyl or methyl;

~~when Z is -CH₂-, R is H, Ph is substituted aryl with the substitutions selected from the group consisting of 4 N(CH₃)₂, 4 OCH₃, H, and 4 CH₃, the N atom of the nitrone is not coupled to methyl;~~

~~when Z is -CH₂-, R is H, Ph is substituted aryl with the substitutions selected from the group consisting of 3,5-di t butyl, 3,4-(OCH₂O)- and H, the N atom of the nitrone is not coupled to t butyl;~~

~~when Z is -CH₂-, R is CH₃, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to methyl or unsubstituted phenyl;~~

~~when Z is -CH₂-, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to unsubstituted phenyl;~~

~~when Z is -CH(CH₃)-, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to methyl, cyclohexyl or unsubstituted phenyl;~~

~~when Z is -CH(CH₃)-, R is H, and Ph is substituted aryl with the substitutions selected from the group consisting of 2,5-dimethoxy, and 2,5-dimethyl, the N atom of the nitrone is not coupled to cyclohexyl; and~~

when Z is -CH₂-(CH₂)₃-, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to cyclohexyl.


10. (previously presented) The nitrone compound of claim 9 wherein Z is a straight chain alkylene.

11. (previously presented) The nitron compound of claim 9 wherein Z is a branched chain alkylene.
12. (cancelled)
13. (previously presented) The nitron compound of claim 10 wherein Z is ethylene.
14. (previously presented) The nitron compound of claim 10 wherein Z is n-propylene.
15. (previously presented) The nitron compound of claim 10 wherein Z is n-butylene.
16. (previously presented) The nitron compound of claim 11 wherein Z is isopropylene.
17. (previously presented) The nitron compound of claim 9 wherein the nitron nitrogen is coupled to a lower alkyl.
18. (previously presented) The nitron compound of claim 17 wherein the lower alkyl is methyl.
19. (previously presented) The nitron compound of claim 17 wherein the lower alkyl is tert-butyl.
20. (currently amended) The nitron compound of claim 10 wherein the aryl moiety is substituted phenyl.
21. (currently amended) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two ~~lower alkyls~~ sulfonyls.

22. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two lower alkyls and one hydroxyl.

23. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two alkoxy.

24. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of formula I as active ingredients.



I

wherein:

- (i) n is an integer with a value ranging from ~~one~~ two to six;
- (ii) each R₁ is independently selected from:
 hydrogen,
 alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, aralkyl, aralkenyl,
 aralkynyl,
 halo, haloalkyl,
 hydroxyl, alkoxyl, hydroxyalkyl, alkoxyalkoxyl, acyl, carboxylate, carboxyl,
 alkanoyloxy,
 nitrate, nitrite, nitrile, cyanate, isocyanate, primary amino, secondary amino,
 tertiary amino, azido, carboxamido, acylamino,
 thiol, sulfonyl, alkyl sulfonate, aryl sulfonate, sulfonamide, thioaryloxy,
 thioalkoxy,
 oxygen heterocycles, nitrogen heterocycles and sulfur heterocycles;
- (iii) R₂, R₃ and R₅ are each independently selected from hydrogen, alkyl and cycloalkyl; and

(iv) R_4 is selected from alkyl, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl and aralkyl.

25. (previously presented) The composition of claim 24 wherein the R_1 groups include hydrogens and from zero up to three nonhydrogens selected from alkyl, alkoxy, alkoxyalkoxyl, halo, hydroxy, amino, dialkylamino, acylamino, sulfonyl, sulfonate, sulfonamide, acyl, and aryl.

26. (previously presented) The composition of claim 24 wherein n is an integer having a value of from 1 through 4.

27. (previously presented) The composition of claim 24 wherein $n = 1$ and R_2 , R_3 and R_5 are together all hydrogen or two hydrogens and one lower alkyl; and materials in which $n=2$ or 3 and R_2 , R_3 and R_5 are all hydrogens and up to two lower alkyls.

28. (previously presented) The composition of claim 24 wherein $n = 1$ and R_2 , R_3 and R_5 are together all hydrogen or two hydrogens and one lower alkyl; and materials in which $n=2$ or 3 and R_2 , R_3 and R_5 are all hydrogens and up to two lower alkyls.

29. (previously presented) The composition of claim 27 wherein R_1 and R_4 are selected from the group consisting of:

R_1	R_4
H	$C(CH_3)_3$
4-Me	$C(CH_3)_3$
4-iso-Pr	$C(CH_3)_3$
4-OH	$C(CH_3)_3$
4-OMe	$C(CH_3)_3$
4-OCH ₂ OMe	$C(CH_3)_3$
4-OEt	$C(CH_3)_3$
4-NMe ₂	$C(CH_3)_3$

R ₁	R ₄
4-NHAc	C(CH ₃) ₃
4-F	C(CH ₃) ₃
4-Cl	C(CH ₃) ₃
2-SO ₃ Na	C(CH ₃) ₃
2,4-di-SO ₃ Na	C(CH ₃) ₃
3,5-di-t-Bu-4-OH	C(CH ₃) ₃
3,5-di-t-Bu-4-OCH ₂ OMe	C(CH ₃) ₃
2-OH	C(CH ₃) ₃
2-OEt	C(CH ₃) ₃

30. (currently amended) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and as active ingredients one or more compounds selected from the group consisting of:

- Compound 1 *N-tert*-butyl-C-(2-phenylethyl) nitrone
- Compound 2 *N-tert*-butyl-C-{2-[4-(methoxymethoxy)phenyl]ethyl} nitrone
- Compound 3 *N-tert*-butyl-C-[2-(4-hydroxyphenyl)ethyl] nitrone
- Compound 4 *N-tert*-butyl-C-[2-(4-methoxyphenyl)ethyl] nitrone
- Compound 5 *N-tert*-butyl-C-[4-(tetrahydropyran-2-yloxy) phenyl] nitrone
- Compound 6 *N-tert*-butyl-C-[2-(4-isopropoxyphenyl)ethyl] nitrone
- Compound 7 *N-tert*-butyl-C-[2-(4-ethoxyphenyl)ethyl] nitrone
- Compound 8 *N-tert*-butyl-C-[2-(4-benzenesulfonyloxy)phenyl]ethyl] nitrone
- Compound 9 *N-tert*-butyl-C-[2-(4-acetamidophenyl)ethyl] nitrone
- Compound 10 *N-tert*-butyl-C-[2-(4-benzenesulfonamidophenyl)ethyl] nitrone
- Compound 11 ~~*N-tert*-butyl-C-[2-(4-N,N-Dibenzenesulfimidophenyl)ethyl] nitrone~~ *N-tert*-butyl-C-[2-(4-N,N-Dibenzenesulfimidophenyl)ethyl] nitrone
- Compound 12 *N-tert*-butyl-C-(5-phenylpentyl) nitrone
- Compound 13 *N-tert*-butyl-C-[2-(4-isopropylphenyl)-1-methylethyl] nitrone
- Compound 14 *N-tert*-butyl-C-(4-phenylpropyl) nitrone
- Compound 15 *N-tert*-butyl-C-[1-(4-*tert*-butyl benzyl)-ethyl] nitrone

- Compound 16 *N-tert-butyl-C-[1-methyl-2-(4-methoxyphenyl)ethyl] nitrone*
Compound 17 *N-tert-butyl-C phenylmethyl nitrone*
Compound 18 *N-cyclohexyl-C-(2-phenylethyl) nitrone*
Compound 19 *N-tert-butyl-C-[4-phenylbutyl] nitrone*
Compound 20 *N-tert-butyl-C-[1-(phenyl)ethyl] nitrone*
Compound 21 *N-tert-butyl-C-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl] nitrone*
Compound 22 *N-tert-butyl-C-[2-(3,5-di-tert-butyl-4-ydroxyphenyl)methyl] nitrone*
Compound 23 *N-tert-butyl-C-[4-methoxy-phenyl)propyl] nitrone,*
and pharmaceutically acceptable salts thereof.

31. (previously presented) A pharmaceutical composition comprising a pharmaceutical carrier and, as an active ingredient at least one nitrone compound, the nitrone compound comprising at least a Ph-Z-C=N(=O) - where Ph represents a substituted or unsubstituted aryl moiety, and Z is a saturated aliphatic carbon chain of one to six carbon atoms in length covalently bonded intermediate the aryl moiety and the nitrone carbon.

32. (previously presented) The pharmaceutical composition of claim 31 wherein Z is a straight chain alkylene.

33. (previously presented) The pharmaceutical composition of claim 31 wherein Z is a branched chain alkylene.

34. (previously presented) The pharmaceutical composition of claim 32 wherein Z is methylene.

35. (previously presented) The pharmaceutical composition of claim 32 wherein Z is ethylene.

36. (previously presented) The pharmaceutical composition of claim 32 wherein Z is n-propylene.

37. (previously presented) The pharmaceutical composition of claim 32 wherein Z is n-butylene.
38. (previously presented) The pharmaceutical composition of claim 32 wherein Z is isopropylene.
39. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the carrier is an injectable carrier.
40. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the composition is a solid carrier.
41. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the composition is a unit dose form.
42. (withdrawn) A method for treating or preventing inflammation in a mammal comprising administering said mammal an effective inflammation treating or preventing dose of a pharmaceutical composition according to any of claims 24-41.
43. (withdrawn) A method for treating or preventing neuropathic pain in a mammal comprising administering said mammal an effective neuropathic pain treating or preventing dose of a pharmaceutical composition according to any of claims 24-41.
44. (withdrawn) A method for the treatment of traumatic injury to the brain or spinal cord of a mammal comprising administering said mammal an effective brain or spinal cord injury treating dose of a pharmaceutical composition according to any of claims 24-41.
45. (withdrawn) The method of any of claims 42-44 wherein the mammal is a human.